Gronghui, April 25丨Valneva (VALN.US) fell more than 15% to $27.76. The company said the EMA's Human Pharmaceutical Products Committee had another list of questions about the company, including requests for additional data and further justification for conditional marketing approval of the vaccine candidate. Thomas Lingelbach, CEO of Valneva, said, “So far, the EMA believes that the materials we have submitted are insufficient, and we are disappointed. We remain fully committed to working with regulators to obtain product approval.”